

## Supplementary Tables and Figures

**Supplementary Table 1.** Demographic, clinical and tumor characteristics among 718 colorectal cancer patients

	All (n=718)	Latino (n=128)	Non-Latino (n=469)	Ethnicity Unknown (n=121)
<b>Study group [n (%)]</b>				
HCCS	27 (3.8)	27 (21.1)	0 (0)	0 (0)
PRBB	56 (7.8)	56 (43.8)	0 (0)	0 (0)
TCC	216 (30.1)	40 (31.2)	173 (36.9)	3 (2.5)
TCGA	419 (58.4)	5 (3.9)	296 (63.1)	118 (97.5)
<b>Sex [n (%)]</b>				
Female	336 (46.8)	51 (39.8)	234 (42.1)	51 (42.1)
Male	382 (53.2)	77 (60.2)	235 (57.9)	70 (57.9)
<b>Age at diagnosis [mean (<math>\pm</math>SD)]</b>	65.2 (12.6)	62.7 (12.9)	64.9 (12.5)	69.4 (11.7)
<b>Age at diagnosis [n (%)]</b>				
<=50	94 (13.1)	20 (15.6)	66 (14.1)	8 (6.6)
>50	624 (86.9)	108 (84.4)	403 (85.9)	113 (93.4)
<b>Primary site [n (%)]</b>				
Colon	534 (74.4)	90 (70.3)	354 (75.5)	90 (74.4)
Rectum	179 (24.9)	37 (28.9)	111 (23.7)	31 (25.6)
Unknown <sup>a</sup>	5 (0.7)	1 (0.8)	4 (0.9)	0 (0)
<b>Stage [n (%)]</b>				
1	105 (14.6)	16 (12.5)	59 (12.6)	30 (24.8)
2	241 (33.6)	37 (28.9)	155 (33.0)	49 (40.5)
3	238 (33.1)	45 (35.2)	169 (36.0)	24 (19.8)
4	98 (13.6)	11 (8.6)	72 (15.4)	15 (12.4)
Unknown	36 (5.0)	19 (14.8)	14 (3.0)	3 (2.5)
<b>Race [n (%)]</b>				
American Indian	1 (0.1)	0 (0)	1 (0.2)	0 (0)
Asian	12 (1.7)	1 (0.8)	9 (1.9)	2 (1.7)
Black	63 (8.8)	4 (3.1)	55 (11.7)	4 (3.3)
Other	6 (0.8)	5 (3.9)	1 (0.2)	0 (0)
White	475 (66.2)	70 (54.7)	402 (85.7)	3 (2.5)
Unknown	161 (22.4)	48 (37.5)	1 (0.2)	112 (92.6)
<b>dMMR/MSI-H status [n (%)] <sup>b</sup></b>				
MSI-H	101 (14.1)	12 (9.4)	77 (16.4)	12 (9.9)
MSS	617 (85.9)	116 (90.6)	392 (83.6)	109 (90.1)
<b>Tumor mutation burden [mean (<math>\pm</math>SD)]</b>				
<sup>c</sup>	328.3 (710.6)	233.9 (389.0)	345.8 (723.3)	360.0 (897.3)
<b>Hypermutation status [n (%)] <sup>d</sup></b>				
Non-hypermutated	609 (84.8)	114 (89.1)	391 (83.4)	104 (86.0)

Hypermutated	109 (15.2)	14 (10.9)	78 (16.6)	17 (14.0)
--------------	------------	-----------	-----------	-----------

<sup>a</sup> Study participants with missing information

<sup>b</sup> For samples with missing clinical information, MSI status was determined by MSIsensor based on a MSI score cutoff of 10% (MSI-H if  $\leq 10\%$ ; MSS if  $> 10\%$ )

<sup>c</sup> Defined as the total number of coding, non-silent mutations per patient

<sup>d</sup> An empirical cutoff of log-transformed mutation load at 6.6 was used to categorize samples into hypermutated( $\log_{10} > 6.6$ ) and non-hypermutated ( $\log_{10} \leq 6.6$ )

Abbreviations:

HCCS = Hispanic Colorectal Cancer Study

PRBB = Puerto Rico Biobank

TCC = Total Cancer Care

TCGA = The Cancer Genome Atlas

**Supplementary Table 2.** Detailed sequencing analysis and quality control characteristics by sample set

Sequencing source	Capture Kit	Sequence Provider	Sequencer	Sequence config	CRC samples (T/N pairs)
ABBV <sup>a</sup>	Agilent Clinical Research Exome	WashU Genomics Technology Access Center	Illumina HiSeq2500 or HiSeq3000	2x150	14
ORIEN AVATAR <sup>a</sup>	IDT xGen + additional probes to provide double coverage on 440 actionable genes	HudsonAlpha	Illumina HiSeq4000	2x101	112
BMS <sup>a</sup>	Agilent SureSelect v5, no UTR 51Mb kit	Expression Analysis	Illumina HiSeq	2x101	90
HCCS	Agilent SureSelect v6 + UTR	Macrogen (via NIH)	NovaSeq 6000	2x151	27
PRBB – FF	IDT xGen Exome	Fulgent	Illumina HiSeq	2x76	24
PRBB – FFPE <sup>b</sup>	NimbleGen SeqCap EZ MedExome	Fulgent	Illumina HiSeq	2x151	32
TCGA	Unknown (used refseq + 25bp flank)	NA	NA	NA	419

<sup>a</sup> TCC (Total Cancer Care) included ABBVIE, AVATAR and BMS cohorts

<sup>b</sup> Normal (non-tumor) samples from 3 PRBB samples were genotyped on the IDT xGen capture kit

Abbreviations:

ABBV = AbbVie Corporation

ORIEN AVATAR = Oncology Research Information Exchange Network Avatar Research Program

BMS = Bristol Myers Squibb

HCCS = Hispanic Colorectal Cancer Study

PRBB = Puerto Rico Biobank

FF = fresh frozen

FFPE = Formalin-Fixed Paraffin-Embedded

TCGA = The Cancer Genome Atlas

**Supplementary Table 3.** Summary of the reference populations from the 1KGP and the PAGE Study

Population	Number of unrelated individuals
<b>1KGP</b>	
Africa	661
Americas <sup>a</sup>	347
East Asia	504
Europe	503
South Asia <sup>a</sup>	489
<b>PAGE Study <sup>b</sup></b>	
Africa	149
America	516
Central/South Asia <sup>a</sup>	201
East-Asia	232
Europe	150
Middle East <sup>a</sup>	163
Oceania <sup>a</sup>	28

<sup>a</sup> The 1KGP samples from Americas and South Asia, and the PAGE Study samples from Central/South Asia, Middle East and Oceania were excluded from the analyses

<sup>b</sup> 178 duplicate samples from PAGE that were also present in 1000 Genomes were excluded from the analyses

Abbreviations:

1KGP = 1000 Genomes Project

PAGE = Population Architecture using Genomics and Epidemiology

**Supplementary Table 4.** List of recurrently mutated genes in sporadic colorectal cancer

Gene symbol	Resources <sup>a</sup>	PMID
	1): Wood et al. Science, 2007	17932254
	2): The Cancer Genome Atlas Network. Nature, 2012	22810696
	3): Guda et al. PNAS, 2015	25583493
	4): Kothari et al. Cancer, 2016	27244218
<i>ACVR1B</i>	2)	
<i>ACVR2A</i>	2)	
<i>APC</i>	1); 2)	
<i>BRAF</i>	2)	
<i>CASP8</i>	2)	
<i>CDC27</i>	2)	
<i>CTNNB1</i>	2)	
<i>EDNRB</i>	2)	
<i>EPHA6</i>	3)	
<i>FAM123B</i>	2)	
<i>FBXW7</i>	1); 2); 4)	
<i>FLCN</i>	3)	
<i>FZD3</i>	2)	
<i>GPC6</i>	2)	
<i>HTF1F</i>	3)	
<i>KIAA1804</i>	2)	
<i>KRAS</i>	1); 2)	
<i>MAP7</i>	2)	
<i>MIER3</i>	2)	
<i>MSH3</i>	2)	
<i>MSH6</i>	2)	
<i>MYO1B</i>	2)	
<i>NRAS</i>	2)	
<i>PIK3CA</i>	1); 2)	
<i>POLE</i>	4)	
<i>PTPN12</i>	2)	
<i>SMAD2</i>	2)	
<i>SMAD4</i>	2)	
<i>SOX9</i>	2)	
<i>TCERG1</i>	2)	
<i>TCF7L2</i>	2)	
<i>TGFBR2</i>	2)	
<i>TP53</i>	1); 2)	
<i>TTN</i>	2)	
<i>WASH1</i>	3)	

<sup>a</sup> The first four rows refer to the selected studies; each number indicates the specific study(ies) where the corresponding gene was identified

**Abbreviations:**

PMID = PubMed identifier

**Supplementary Table 5.** Estimated average genetic ancestry in 718 colorectal cancer patients by ethnicity

Mean (min-max) of ancestry % <sup>b</sup>	All (n=718)	Ethnicity <sup>a</sup>		p-value <sup>c</sup>
		Latino (n=128)	Non-Latino (n=469)	
AFR	9.9 (0-100)	15.2 (0.001-95.9)	10.1 (0.001-99.9)	<2.2x10 <sup>-16</sup>
NAT	4.0 (0-85.1)	20.2 (0.001-85.1)	0.5 (0.001-69.6)	<2.2x10 <sup>-16</sup>
EAS	2.4 (0-100)	1.8 (0.001-97.4)	2.5 (0.001-99.9)	0.093
EUR	83.8 (0-100)	62.8 (2.6-98.0)	86.9 (0.001-99.9)	0.11

<sup>a</sup> Samples with unknown ethnicity (n=121) were excluded

<sup>b</sup> Genetic ancestry was estimated through a supervised model in ADMIXTURE-1.3.0 and assuming K=4

<sup>c</sup> t-test on log transformed variables

Abbreviations:

AFR = African

EAS = East Asian

EUR = European

NAT = Native American

**Supplementary Table 6.** Estimated average genetic ancestry in 718 colorectal cancer patients by contributing study

Mean (range) of ancestry % <sup>b</sup>	All (n=718)	Study cohort <sup>a</sup>			
		HCCS (n=27)	PRBB (n=56)	TCC (n=216)	TCGA (n=419)
EUR	83.8 (0-100)	50.1 (2.6-77.8)	66.9 (27.7-88.8)	89.5 (2.7-100)	85.3 (0-100)
EAS	2.3 (0-100)	5.9 (0-97.4)	0.4 (0-2.3)	1.1 (0-97.3)	3.0 (0-100)
AFR	9.9 (0-100)	5.1 (0-11.2)	19.6 (2.7-66.9)	5.3 (0-94.9)	11.2 (0-100)
AMR	4.0 (0-85.1)	38.9 (0-65.5)	13.2 (4.9-24.9)	4.0 (0-85.1)	0.4 (0-16.4)

<sup>a</sup> Samples with unknown ethnicity (n=121) were included

<sup>b</sup> Genetic ancestry was estimated through  
a supervised model in ADMIXTURE-1.3.0  
and assuming K=4

Abbreviations:

HCCS = Hispanic Colorectal Cancer Study

PRBB = Puerto Rico Biobank

TCC = Total Cancer Care

TCGA = The Cancer Genome Atlas

**Supplementary Table 7.** Association between genetic ancestry and recurrently mutated genes in 718 colorectal cancer patients

Gene <sup>a</sup>	Total variants <sup>b</sup>	Carriers <sup>c</sup>	Frequency <sup>d</sup>	Compositional data analysis		AFR ancestry		EAS ancestry		EUR ancestry		NAT ancestry	
				LRT raw p-value <sup>e,i</sup>	LRT FDR p-value <sup>f,j</sup>	OR (95%CI) <sup>g,j</sup>	p-value <sup>h,j</sup>	OR (95%CI)	p-value	OR (95%CI)	p-value	OR (95%CI)	p-value
CDC27	5	4	0.0056	<b>0.0084</b>	0.2075		0.9960		0.9976		0.9953		0.9966
PTPN12	14	18	0.0251	0.0660	0.4011	0.92 (0.71; 1.19)	0.5440		0.9942	1.16 (0.92; 1.46)	0.2224	0.73 (0.35; 1.5)	0.3920
MIER3	12	13	0.0181	0.0719	0.4146	0.6 (0.18; 2.02)	0.4112		0.9948	1.47 (0.82; 2.65)	0.1961	0.6 (0.14; 2.59)	0.4937
TCF7L2	60	82	0.1142	0.0795	0.4256	0.93 (0.82; 1.05)	0.2403	0.95 (0.75; 1.21)	0.6809	1.08 (0.98; 1.19)	0.1413	0.93 (0.72; 1.21)	0.6050
PIK3CA	70	150	0.2089	0.1255	0.5036	1.06 (0.98; 1.14)	0.1306	0.99 (0.85; 1.16)	0.9302	0.98 (0.91; 1.04)	0.4878	0.87 (0.67; 1.11)	0.2641
MAP7	17	16	0.0223	<b>0.1837</b>	0.5803	1.03 (0.85; 1.27)	0.7424	1.27 (1.04; 1.55)	<b>0.0185</b>	0.89 (0.77; 1.04)	0.1406	0.9 (0.5; 1.61)	0.7124
TCERG1	34	55	0.0766	0.2072	0.6091	0.96 (0.83; 1.1)	0.5182		0.9866	1.1 (0.97; 1.25)	0.1462	0.83 (0.54; 1.29)	0.4132
NRAS	14	42	0.0585	0.2605	0.6649	1.01 (0.87; 1.17)	0.9090	0.82 (0.39; 1.75)	0.6115	1.02 (0.9; 1.16)	0.7512	0.77 (0.48; 1.23)	0.2762
SMAD2	27	27	0.0376	0.3329	0.7195	1.14 (1; 1.3)	<b>0.0462</b>		0.9904	0.93 (0.82; 1.05)	0.2517	0.8 (0.45; 1.43)	0.4543
KIAA1804	39	39	0.0543	0.3374	0.7232	0.96 (0.81; 1.13)	0.6232		0.9906	1.11 (0.95; 1.31)	0.1866	0.54 (0.22; 1.32)	0.1744
FZD3	14	14	0.0195	0.4407	0.7900	1.13 (0.95; 1.33)	0.1674		0.9921	0.94 (0.79; 1.12)	0.5052	0.68 (0.26; 1.76)	0.4269
SMAD4	72	85	0.1184	0.4478	0.7948	0.99 (0.9; 1.1)	0.8908	1.09 (0.91; 1.3)	0.3657	1 (0.92; 1.1)	0.9444	0.92 (0.69; 1.22)	0.5754
APC	430	527	0.7340	<b>0.4679</b>	0.8052	1.07 (0.98; 1.16)	0.1170	0.91 (0.79; 1.04)	0.1604	0.97 (0.91; 1.04)	0.4043	1.04 (0.86; 1.27)	0.6744
GPC6	17	17	0.0237	0.4794	0.8118	0.9 (0.67; 1.2)	0.4737		0.9912	1.14 (0.89; 1.46)	0.2966	0.86 (0.4; 1.84)	0.6889
ACVR2A	28	102	0.1421	<b>0.4883</b>	0.8166	0.99 (0.9; 1.09)	0.8080	1.1 (0.95; 1.27)	0.2257	1 (0.92; 1.08)	0.9955	0.83 (0.6; 1.15)	0.2602
FBXW7	72	97	0.1351	0.4890	0.8170	1 (0.91; 1.1)	0.9772	1.03 (0.86; 1.22)	0.7819	1.03 (0.94; 1.12)	0.5133	0.71 (0.48; 1.04)	0.0823
FLCN	15	31	0.0432	0.4951	0.8209	1.03 (0.89; 1.2)	0.6621		0.9936	1.02 (0.88; 1.18)	0.8047	0.53 (0.16; 1.74)	0.2955
BRAF	17	82	0.1142	<b>0.5197</b>	0.8357	0.95 (0.84; 1.06)	0.3418	1.12 (0.93; 1.34)	0.2266	1.05 (0.95; 1.16)	0.3701	0.42 (0.17; 1.05)	0.0630
MYO1B	21	18	0.0251	0.5286	0.8389	0.72 (0.39; 1.32)	0.2840	1.15 (0.87; 1.51)	0.3204	1.05 (0.86; 1.29)	0.6161	0.97 (0.56; 1.68)	0.9104
EDNRB	25	31	0.0432	0.5525	0.8520	1.01 (0.88; 1.17)	0.8572		0.9913	1.02 (0.89; 1.17)	0.7989	0.88 (0.52; 1.49)	0.6324
TP53	174	388	0.5404	0.6221	0.8847	1.03 (0.97; 1.1)	0.3252	0.94 (0.81; 1.09)	0.3963	1 (0.94; 1.05)	0.8671	0.94 (0.8; 1.11)	0.4794
POLE	58	49	0.0682	<b>0.6749</b>	0.9062	0.98 (0.85; 1.12)	0.7199	0.97 (0.76; 1.23)	0.7790	1.03 (0.92; 1.15)	0.6629	0.99 (0.72; 1.36)	0.9675
TGFBR2	21	29	0.0404	0.7045	0.9171	1.08 (0.94; 1.24)	0.2902	0.99 (0.75; 1.29)	0.9240	0.95 (0.83; 1.07)	0.3896	1.08 (0.73; 1.58)	0.7058
KRAS	29	291	0.4053	0.7188	0.9216	1.05 (0.98; 1.12)	0.1439	0.94 (0.81; 1.09)	0.3988	0.97 (0.92; 1.03)	0.3778	1.02 (0.86; 1.2)	0.8295
FAM123B	52	72	0.1003	0.7201	0.9216	1.04 (0.95; 1.15)	0.4039	0.78 (0.47; 1.29)	0.3329	0.99 (0.9; 1.08)	0.7622	1.06 (0.8; 1.39)	0.6841
TTN	952	346	0.4819	0.8250	0.9562	0.98 (0.91; 1.04)	0.4555	0.99 (0.87; 1.14)	0.9102	1.01 (0.96; 1.07)	0.7048	1.12 (0.95; 1.32)	0.1865
MSH6	26	38	0.0529	0.8451	0.9600	1 (0.87; 1.16)	0.9484	0.97 (0.74; 1.27)	0.8237	0.99 (0.88; 1.12)	0.9182	1.06 (0.74; 1.53)	0.7431

CASP8	27	28	0.0390	0.8478	0.9604	1.01 (0.86; 1.19)	0.8725	1.07 (0.84; 1.37)	0.5780	0.96 (0.84; 1.1)	0.5535	1.15 (0.76; 1.76)	0.5051
CTNNB1	45	50	0.0696	0.8558	0.9617	1.07 (0.96; 1.19)	0.2065	0.95 (0.75; 1.2)	0.6671	0.97 (0.88; 1.07)	0.4959	0.8 (0.52; 1.23)	0.3124
SOX9	87	91	0.1267	0.9207	0.9793	1.03 (0.94; 1.13)	0.5672	1.06 (0.89; 1.27)	0.5212	0.98 (0.9; 1.06)	0.5850	0.96 (0.72; 1.27)	0.7783
ACVR1B	28	24	0.0334	0.9314	0.9810	0.97 (0.8; 1.18)	0.7404	1.22 (1.03; 1.45)	<b>0.0223</b>	0.94 (0.82; 1.07)	0.3627	0.59 (0.21; 1.65)	0.3119
MSH3	19	49	0.0682	0.9608	0.9886	1.03 (0.91; 1.16)	0.6732	1.07 (0.89; 1.28)	0.4854	0.95 (0.86; 1.05)	0.3557	1.04 (0.75; 1.45)	0.8101
EPHA6	42	38	0.0529	0.9693	0.9903	1.01 (0.87; 1.16)	0.9410		0.9904	1.02 (0.9; 1.16)	0.7537	1.03 (0.71; 1.47)	0.8905

<sup>a</sup> Genes ordered by increasing LRT p-value; only genes with mutations in ≥3 carriers were retained

<sup>b</sup> Number of variants identified in each gene

<sup>c</sup> Number of mutation carriers

<sup>d</sup> Frequency of mutation carriers

<sup>e</sup> P-value from the 3-degree of freedom likelihood-ratio test (LRT) using compositional data analysis in the context of logistic regression

<sup>f</sup> False Discovery Rate (FDR) correction performed by the Benjamini-Hochberg procedure

<sup>g</sup> Odds ratio (OR) and 95% confidence interval (CI) for association between gene mutation status and each 10% increase in genetic ancestry; risk estimates not presented when the ancestry proportion among carriers is extremely low

<sup>h</sup> P-value from the Wald test in logistic regression model

<sup>i</sup> All models were adjusted for age at diagnosis, sex, tumor location, and tumor stage

#### Abbreviations:

AFR = African

EAS = Asian

EUR = European

NAT = Native American

LRT = likelihood ratio test

FDR = false discovery rate

OR = odds ratio

CI = confidence interval

**Supplementary Table 8.** Association between ethnicity and recurrently mutated genes in 718 colorectal cancer patients

Gene <sup>a</sup>	All patients (n=597)			Latino (n=128)		non-Latino (n=469)		OR (95%CI) <sup>e,g</sup>	p-value <sup>f,g</sup>
	Total variants <sup>b</sup>	Carriers <sup>c</sup>	Frequency <sup>d</sup>	Carriers	Frequency	Carriers	Frequency		
<b>CDC27</b>									
PTPN12	14	18	0.0251	2	0.0156	9	0.0192	0.58 (0.11; 3.05)	0.5198
MIER3	12	13	0.0181	1	0.0078	6	0.0128	0.82 (0.1; 7.05)	0.8555
TCF7L2	60	82	0.1142	12	0.0938	57	0.1215	0.7 (0.35; 1.39)	0.3085
PIK3CA	70	150	0.2089	17	0.1328	107	0.2281	0.55 (0.31; 0.98)	<b>0.0431</b>
MAP7	17	16	0.0223	2	0.0156	10	0.0213	0.66 (0.13; 3.3)	0.6134
TCERG1	34	55	0.0766	7	0.0547	40	0.0853	0.66 (0.28; 1.57)	0.3506
NRAS	14	42	0.0585	8	0.0625	23	0.0490	1.36 (0.56; 3.27)	0.4982
SMAD2	27	27	0.0376	4	0.0313	16	0.0341	0.92 (0.29; 2.94)	0.8854
KIAA1804	39	39	0.0543	7	0.0547	26	0.0554	0.96 (0.39; 2.34)	0.9283
FZD3	14	14	0.0195	3	0.0234	7	0.0149	1.37 (0.33; 5.72)	0.6670
SMAD4	72	85	0.1184	9	0.0703	66	0.1407	0.48 (0.23; 1.04)	0.0624
APC	430	527	0.7340	93	0.7266	357	0.7612	0.79 (0.5; 1.25)	0.3110
GPC6	17	17	0.0237	2	0.0156	14	0.0299	0.55 (0.12; 2.51)	0.4421
ACVR2A	28	102	0.1421	14	0.1094	73	0.1557	0.72 (0.38; 1.37)	0.3164
FBXW7	72	97	0.1351	13	0.1016	67	0.1429	0.62 (0.32; 1.19)	0.1507
FLCN	15	31	0.0432	5	0.0391	23	0.0490	0.83 (0.28; 2.39)	0.7238
BRAF	17	82	0.1142	9	0.0703	66	0.1407	0.56 (0.26; 1.21)	0.1406
MYO1B	21	18	0.0251	5	0.0391	9	0.0192	2.14 (0.66; 6.91)	0.2025
EDNRB	25	31	0.0432	5	0.0391	22	0.0469	0.95 (0.35; 2.62)	0.9254
TP53	174	388	0.5404	67	0.5234	272	0.5800	0.68 (0.45; 1.04)	0.0738
POLE	58	49	0.0682	8	0.0625	31	0.0661	1.01 (0.44; 2.33)	0.9732
TGFBR2	21	29	0.0404	6	0.0469	21	0.0448	0.97 (0.36; 2.64)	0.9565
KRAS	29	291	0.4053	46	0.3594	205	0.4371	0.64 (0.41; 0.97)	<b>0.0374</b>
FAM123B	52	72	0.1003	10	0.0781	50	0.1066	0.73 (0.35; 1.54)	0.4101
TTN	952	346	0.4819	65	0.5078	229	0.4883	1.17 (0.78; 1.76)	0.4454
MSH6	26	38	0.0529	9	0.0703	24	0.0512	1.73 (0.75; 3.96)	0.1976
CASP8	27	28	0.0390	4	0.0313	19	0.0405	0.8 (0.26; 2.46)	0.7022
CTNNB1	45	50	0.0696	8	0.0625	39	0.0832	0.7 (0.31; 1.59)	0.3915
SOX9	87	91	0.1267	13	0.1016	67	0.1429	0.65 (0.33; 1.27)	0.2085
ACVR1B	28	24	0.0334	5	0.0391	15	0.0320	1.23 (0.42; 3.63)	0.7108
MSH3	19	49	0.0682	10	0.0781	32	0.0682	1.24 (0.57; 2.67)	0.5905
EPHA6	42	38	0.0529	6	0.0469	29	0.0618	0.82 (0.33; 2.08)	0.6785

<sup>a</sup> Genes ordered by increasing LRT p-value from exome-wide association with genetic ancestry; lines are blank for genes with no mutations in Latinos or non-Latinos

<sup>b</sup> Number of variants identified in each gene

<sup>c</sup> Number of mutation carriers

<sup>d</sup> Frequency of mutation carriers

<sup>e</sup> Odds ratio (OR) and 95% confidence interval (CI) for association between gene mutation status and ethnicity

<sup>f</sup> P-value from the Wald test in logistic regression model; p-values <0.05 are highlighted in bold

<sup>g</sup> All models were adjusted for age at diagnosis, sex, tumor location, and tumor stage

Abbreviations:

OR = odds ratio

CI = confidence interval

**Supplementary Table 9.** Characteristics of individual somatic mutations in ancestry associated genes in 718 colorectal cancer patients

Base change	Carriers <sup>a</sup>	Frequency <sup>b</sup>	Gene	Amino acid change	Chromosome	Position	Functional effect
c.685delC	1	0.0014	TMEM184B	p.Q229fs/frameshift_deletion	22	38620890	frameshift deletion
c.C280T	1	0.0014	TMEM184B	p.L94F/nonsynonymous_SNV	22	38626722	nonsynonymous SNV
c.G647A	1	0.0014	TMEM184B	p.R216H/nonsynonymous_SNV	22	38620929	nonsynonymous SNV
c.G181A	1	0.0014	KNCN	p.A61T/ncRNA_intronic	1	47014910	nonsynonymous SNV
c.C11T	1	0.0014	KNCN	p.P4L/ncRNA_intronic	1	47016877	nonsynonymous SNV
c.G20A	1	0.0014	KNCN	p.S7N/ncRNA_intronic	1	47016868	nonsynonymous SNV
c.292delG	2	0.0028	KNCN	p.A98fs/ncRNA_intronic	1	47013415	frameshift deletion
c.181delG	1	0.0014	KNCN	p.A61fs/ncRNA_intronic	1	47014909	frameshift deletion
c.C116T	1	0.0014	KNCN	p.A39V/ncRNA_intronic	1	47016772	nonsynonymous SNV

<sup>a</sup> Number of mutation carriers<sup>b</sup> Frequency of mutation carriers

**Supplementary Table 10.** Association between genetic ancestry (for each 10% increase) with TMB and dMMR/MSI status in 718 colorectal cancer patients

	Compositional data analysis		AFR ancestry		EAS ancestry		EUR ancestry		NAT ancestry	
	LRT p-value <sup>a,d</sup>	OR (95%CI) <sup>b,d</sup>	p-value <sup>c,d</sup>	OR (95%CI)	p-value	OR (95%CI)	p-value	OR (95%CI)	p-value	
TMB	0.4702	1.01 (0.97; 1.04)	0.7828	0.98 (0.9; 1.06)	0.5711	1 (0.97; 1.03)	0.9546	0.99 (0.91; 1.09)	0.9169	
dMMR/MSI status	0.0942	0.97 (0.88; 1.07)	0.5287	0.99 (0.83; 1.19)	0.9296	1.04 (0.96; 1.14)	0.3394	0.83 (0.59; 1.18)	0.2983	

<sup>a</sup> P-value from the 3-degree of freedom likelihood-ratio test (LRT) using compositional data analysis in the context of logistic regression

<sup>b</sup> Odds ratio (OR) and 95% confidence interval (CI) for association between TMB or dMMR/MSI and each 10% increase of genetic ancestry

<sup>c</sup> P-value from the Wald test in logistic regression model

<sup>d</sup> All models were adjusted for age at recruitment, sex, tumor location, and tumor stage

Abbreviations:

TMB = tumor mutation burden

dMMR = deficient mismatch repair

MSI = microsatellite instability

AFR = African

EAS = Asian

EUR = European

NAT = Native American

LRT = likelihood ratio test

OR = odds ratio

CI = confidence interval

**Supplementary Table 11.** Association between genetic ancestry and gene mutation status in hypermutated and non-hypermutated patients

Gene <sup>a</sup>	Total variants <sup>b</sup>	Carriers <sup>c</sup>	Frequency <sup>d</sup>	Compositional data analysis		AFR ancestry		EAS ancestry		EUR ancestry		NAT ancestry	
				LRT raw p-value <sup>e,j</sup>	LRT FDR p-value <sup>f,i</sup>	OR (95%CI) <sup>g,j</sup>	p-value <sup>h,i</sup>	OR (95%CI)	p-value	OR (95%CI)	p-value	OR (95%CI)	p-value
<b>Non-hypermutated (n=609)</b>													
TMEM184B	3	3	0.0049	2.89x10 <sup>-06</sup>	<b>0.0012</b>	1.52 (1.09; 2.11)	<b>0.0140</b>		0.9994	0.66 (0.46; 0.96)	0.0283	1.27 (0.49; 3.27)	0.6210
UBA2	2	4	0.0066	0.0080	0.22		0.9941		0.9981		0.9957		0.9968
TRMT5	4	3	0.0049	0.0079	0.22		0.9961		0.9986		0.9952		0.9967
RPRD1B	3	3	0.0049	0.0042	0.17		0.9957		0.9985		0.9966		0.9961
<b>Hypermutated (n=109)</b>													
C1QC	4	4	0.0367	9.25x10 <sup>-57</sup>	<b>1.53x10<sup>-54</sup></b>		0.9957		1.0000		0.9965		0.9987
COX4I2	4	3	0.0275	0.026	0.21		0.9971		0.9985		0.9965		0.9973
FTHL17	3	3	0.0275	6.89x10 <sup>-28</sup>	<b>5.35x10<sup>-26</sup></b>		0.9986		0.9995		0.9980		0.9993
ACOT4	3	3	0.0275	8.44x10 <sup>-05</sup>	<b>0.0042</b>		0.9980		0.9991		0.9968		0.9986
BCL6	11	14	0.1284	6.93x10 <sup>-07</sup>	<b>4.66x10<sup>-05</sup></b>		0.9929		0.9959		0.9943		0.9927
C6orf106	3	3	0.0275	1.18x10 <sup>-42</sup>	<b>1.32x10<sup>-40</sup></b>		0.9970		0.9994		0.9970		0.9987
UBA2	6	6	0.0550	0.0033	0.068		0.9955		0.9980		0.9962		0.9969
XPO1	12	12	0.1101	2.71x10 <sup>-268</sup>	<b>5.65x10<sup>-265</sup></b>		0.9922		0.9959		0.9927		0.9926
TLX1NB	3	3	0.0275	0.022	0.19	1.41 (0.17; 11.64)	0.7523		0.9968		0.9979		0.9970
GPR21	6	6	0.0550	9.02x10 <sup>-07</sup>	<b>6.04x10<sup>-05</sup></b>		0.9955		0.9989		0.9946		0.9979
GREM2	4	5	0.0459	5.15x10 <sup>-08</sup>	<b>3.50x10<sup>-06</sup></b>		0.9957		0.9977		0.9946		0.9958
TRMT5	5	5	0.0459	0.0064	0.10		0.9955		0.9984		0.9970		0.9972
USP6NL	9	10	0.0917	0.00033	<b>0.013</b>		0.9927		0.9974		0.9944		0.9954
ARL8B	6	6	0.0550	2.12x10 <sup>-69</sup>	<b>5.08x10<sup>-67</sup></b>		0.9948		0.9979		0.9950		0.9958
NR2F2	9	9	0.0826	9.53x10 <sup>-05</sup>	<b>0.0047</b>		0.9936	1.48 (1; 2.18)	0.0504	1.01 (0.75; 1.36)	0.9610		0.9956
TIMM50	5	5	0.0459	2.42x10 <sup>-71</sup>	<b>6.32x10<sup>-69</sup></b>		0.9958		0.9989		0.9967		0.9979
AKIRIN2	5	6	0.0550	8.98x10 <sup>-05</sup>	<b>0.0044</b>		0.9961		0.9986		0.9946		0.9980
B3GNT8	3	3	0.0275	0.43	0.73		0.9989		0.9997		0.9990		0.9996
DNAJC1	5	5	0.0459	0.020	0.18		0.9960		0.9989		0.9967		0.9986

LOC728819	<sup>b</sup> 11	<sup>c</sup> 9	0.0826	0.00050	<b>0.018</b>		0.9933	0.9975	0.9945	0.9957
PRRD1B	4	4	0.0367	$1.07 \times 10^{-42}$	<b><math>1.23 \times 10^{-40}</math></b>		0.9975	0.9996	0.9979	0.9983
TPD52	5	5	0.0459	$6.43 \times 10^{-71}$	<b><math>1.65 \times 10^{-68}</math></b>		0.9957	0.9991	0.9965	0.9978
CD244	6	6	0.0550	0.0015	<b>0.042</b>		0.9955	0.9977	0.9944	0.9956
CDH24	12	10	0.0917	0.0054	0.092		0.9933	0.9980	0.9945	0.9955
DPP8	14	12	0.1101	0.0024	0.057		0.9931	0.9963	0.9944	0.9930
KNCN	4	5	0.0459	0.00026	<b>0.011</b>	1.62 (1.18; 2.23)	0.0029	0.9984	0.74 (0.57; 0.95)	0.0195
SEPT11	8	9	0.0826	0.0049	0.086		0.9932	0.9982	0.9946	0.9968
C3orf23	8	8	0.0734	0.011	0.14		0.9932	0.9964	0.9946	0.9934
SLC9B2	11	9	0.0826	0.00040	<b>0.015</b>		0.9935	1.25 (0.89; 1.76)	0.1940	1.05 (0.78; 1.4)
TMEM143	4	3	0.0275	$1.25 \times 10^{-41}$	<b><math>1.09 \times 10^{-39}</math></b>		0.9959	1.0000	0.9967	0.9972

<sup>a</sup> Genes ordered by increasing LRT p-value from exome-wide association with genetic ancestry (Table 1); only genes with mutations in  $\geq 3$  carriers were retained

<sup>b</sup> Number of variants identified in each gene

<sup>c</sup> Number of mutation carriers

<sup>d</sup> Frequency of mutation carriers

<sup>e</sup> P-value from the 3-degree of freedom likelihood-ratio test (LRT) using compositional data analysis in the context of logistic regression

<sup>f</sup> False Discovery Rate (FDR) correction performed by the Benjamini-Hochberg procedure

<sup>g</sup> Odds ratio (OR) and 95% confidence interval (CI) for association between gene mutation status and each 10% increase in genetic ancestry; risk estimates not presented when the ancestry proportion among carriers is extremely low

<sup>h</sup> P-value from the Wald test in logistic regression model

<sup>i</sup> All models were adjusted for age at diagnosis, sex, tumor location, and tumor stage

#### Abbreviations:

AFR = African

EAS = Asian

EUR = European

NAT = Native American


LRT = likelihood ratio test

FDR = false discovery rate

OR = odds ratio

CI = confidence interval


**Supplementary Figure 1**



**Supplementary Figure 1.** Tumor mutational burden distribution in 718 colorectal cancer patients.

Bar colors indicate MSI score <10 (green) or  $\geq 10$  (red) for each patient. Using the dMMR/MSI status based on the MSI score, we defined an empirical cutoff of log-transformed TMB at 6.2 (blue dotted line) to categorize patients into hypermutated ( $\leq 6.2$ , n=109) and non-hypermutated ( $>6.2$ , n=609) groups.

## Supplementary Figure 2




**Supplementary Figure 2.** Estimated genetic ancestry for 718 colorectal cancer patients stratified by study cohort

A. Genetic ancestry composition for Latino vs non-Latino patients estimated through a supervised model in Admixture assuming K=4. Each patient is represented by a column partitioned into different colors corresponding to the genetic ancestral component (European = blue; African = dark green; East Asian = orange; Amerindian = red). Patients in each ethnic group are ordered by the major ancestral component in decreasing order.

B. Boxplots show the distribution of each ancestral component in Latino and non-Latino patients separately. Median ancestry value is represented as a solid line, interquartile range [IQR] as a box, and whiskers extend up to 1.5\*IQR from the upper and lower quartiles. Potential outliers are depicted as solid points.

#### Supplementary Figure 4

APC



TP53




KRAS



**Supplementary Figure 4.** Mutation spectrum of *APC*, *TP53*, and *KRAS* in 718 colorectal cancer patients

Lollipop-style mutation diagrams show the distribution of somatic mutation across genes. Only mutations with protein change predictions are presented. Each mutation consists of a vertical line with a dot at the higher end. Black dots correspond to truncating mutations, while green dots correspond to nonsynonymous mutations. X-axis: codon position; Y-axis: number of mutation carriers. Colored boxes represent protein domains/motifs.


## Supplementary Figure 5



**Supplementary Figure 5.** Mutational landscape in 128 Latino colorectal cancer patients


- A. Percentage of mutations by total number of bases in each gene. Each point in the plot represents a gene. Genes at the top left of the plot (APC, TP53, KRAS) have a higher mutation rate relative to the gene length.
- B. Top 50 genes with the highest standardized residual from robust regression analysis. Each bar in the plot represents a gene. APC, TP53, and KRAS were the most mutated genes.
- C. Oncoprint of the top mutated genes from robust regression analysis. Each column represents an individual patient. Red=missense mutation; Black=protein truncating mutation.

### Supplementary Figure 6




**Supplementary Figure 6.** Correlation between genetic ancestry and gene mutation status in 718 colorectal cancer patients. Average proportions of AFR (dark green), NAT (red), EAS (orange) and EUR (blue) ancestries are shown for genes with wild-type (wt) and mutated (mut) status. Boxplot lines reflect lower quartile, median, and upper quartile of ancestry, with extended points representing outliers. X-axis: mutation status (wild-type, mutated); Y-axis: genetic ancestry proportions ranging from 0 to 1. P-values from the Wald test in standard logistic regression model.

### Supplementary Figure 7



**Supplementary Figure 7.** Mutation frequency for TMEM184B and KNCN in 718 colorectal cancer patients by ethnicity. Histograms represent the proportion of patients with at least one mutation in the genes. Differences in proportions between Latinos and non-Latinos patients were tested using the Wald test from logistic regression model. P-values at different levels of statistical significance are indicated above histograms: \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ . Mutation rates in TMEM184B and KNCN reveal no significant difference between Latino and non-Latino patients.

**Supplementary Figure 8**



**Supplementary Figure 8.** MSI score by clinically determined dMMR/MSI status (MSS vs MSI vs unknown) in 718 colorectal cancer patients. X-axis: clinical status from medical records; Y-axis: MSI score determined by MSIsensor.